Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Circulating biomarkers for early detection and clinical management of colorectal cancer.

Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE, Stoecklein NH, Heitzer E, Gironella M.

Mol Aspects Med. 2019 Jun 14. pii: S0098-2997(19)30009-3. doi: 10.1016/j.mam.2019.06.002. [Epub ahead of print] Review.

2.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.

Nature. 2019 May 29. doi: 10.1038/s41586-019-1272-6. [Epub ahead of print]

PMID:
31142840
3.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

4.

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH.

Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.

PMID:
30735634
5.

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

van den Broek E, den Uil SH, Coupé VMH, Delis-van Diemen PM, Bolijn AS, Bril H, Stockmann HBAC, van Grieken NCT, Meijer GA, Fijneman RJA.

Oncotarget. 2018 Jun 29;9(50):29445-29452. doi: 10.18632/oncotarget.25655. eCollection 2018 Jun 29.

6.

Consensus molecular subtype classification of colorectal adenomas.

Komor MA, Bosch LJ, Bounova G, Bolijn AS, Delis-van Diemen PM, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, van Grieken NC, Carvalho B, Wessels LF, Jimenez CR, Fijneman RJ, Meijer GA; NGS-ProToCol Consortium:.

J Pathol. 2018 Nov;246(3):266-276. doi: 10.1002/path.5129. Epub 2018 Aug 31.

7.

Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer.

Jacobsen A, Bosch LJW, Martens-de Kemp SR, Carvalho B, Sillars-Hardebol AH, Dobson RJ, de Rinaldis E, Meijer GA, Abeln S, Heringa J, Fijneman RJA, Feenstra KA.

Sci Rep. 2018 May 14;8(1):7522. doi: 10.1038/s41598-018-24982-z.

8.

Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas.

Carvalho B, Diosdado B, Terhaar Sive Droste JS, Bolijn AS, Komor MA, de Wit M, Bosch LJW, van Burink M, Dekker E, Kuipers EJ, Coupé VMH, van Grieken NCT, Fijneman RJA, Meijer GA.

Cancer Prev Res (Phila). 2018 Jul;11(7):403-412. doi: 10.1158/1940-6207.CAPR-17-0317. Epub 2018 Apr 23.

PMID:
29685877
9.

Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.

Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, Laclé MM, Sanders J, Fijneman RJA, Elias SG, Borel Rinkes IHM, Aalbers AGJ, Kranenburg O.

Br J Surg. 2018 Jan;105(2):e204-e211. doi: 10.1002/bjs.10788.

PMID:
29341165
10.

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.

Bosch LJW, de Wit M, Pham TV, Coupé VMH, Hiemstra AC, Piersma SR, Oudgenoeg G, Scheffer GL, Mongera S, Sive Droste JT, Oort FA, van Turenhout ST, Larbi IB, Louwagie J, van Criekinge W, van der Hulst RWM, Mulder CJJ, Carvalho B, Fijneman RJA, Jimenez CR, Meijer GA.

Ann Intern Med. 2017 Dec 19;167(12):855-866. doi: 10.7326/M17-1068. Epub 2017 Nov 21.

PMID:
29159365
11.

Systematically linking tranSMART, Galaxy and EGA for reusing human translational research data.

Zhang C, Bijlard J, Staiger C, Scollen S, van Enckevort D, Hoogstrate Y, Senf A, Hiltemann S, Repo S, Pipping W, Bierkens M, Payralbe S, Stringer B, Heringa J, Stubbs A, Bonino Da Silva Santos LO, Belien J, Weistra W, Azevedo R, van Bochove K, Meijer G, Boiten JW, Rambla J, Fijneman R, Spalding JD, Abeln S.

F1000Res. 2017 Aug 16;6. pii: ELIXIR-1488. doi: 10.12688/f1000research.12168.1. eCollection 2017.

12.

Direct detection of early-stage cancers using circulating tumor DNA.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415.

PMID:
28814544
13.

Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify.

Komor MA, Pham TV, Hiemstra AC, Piersma SR, Bolijn AS, Schelfhorst T, Delis-van Diemen PM, Tijssen M, Sebra RP, Ashby M, Meijer GA, Jimenez CR, Fijneman RJA.

Mol Cell Proteomics. 2017 Oct;16(10):1850-1863. doi: 10.1074/mcp.TIR117.000056. Epub 2017 Jul 26.

14.

GeneBreak: detection of recurrent DNA copy number aberration-associated chromosomal breakpoints within genes.

van den Broek E, van Lieshout S, Rausch C, Ylstra B, van de Wiel MA, Meijer GA, Fijneman RJA, Abeln S.

Version 2. F1000Res. 2016 Sep 19 [revised 2017 Jan 1];5:2340. doi: 10.12688/f1000research.9259.2. eCollection 2016.

15.

Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.

de Wit M, Carvalho B, Delis-van Diemen PM, van Alphen C, Beliën JAM, Meijer GA, Fijneman RJA.

PLoS One. 2017 May 8;12(5):e0174768. doi: 10.1371/journal.pone.0174768. eCollection 2017.

16.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJA, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2017 Jun 15;36(24):3504. doi: 10.1038/onc.2017.3. Epub 2017 Feb 13.

PMID:
28192405
17.

Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

den Uil SH, Coupé VM, Linnekamp JF, van den Broek E, Goos JA, Delis-van Diemen PM, Belt EJ, van Grieken NC, Scott PM, Vermeulen L, Medema JP, Bril H, Stockmann HB, Cormier RT, Meijer GA, Fijneman RJ.

Br J Cancer. 2016 Dec 6;115(12):1565-1574. doi: 10.1038/bjc.2016.376. Epub 2016 Nov 17.

18.

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.

van den Broek E, Krijgsman O, Sie D, Tijssen M, Mongera S, van de Wiel MA, Belt EJ, den Uil SH, Bril H, Stockmann HB, Ylstra B, Carvalho B, Meijer GA, Fijneman RJ.

Oncotarget. 2016 Nov 8;7(45):73876-73887. doi: 10.18632/oncotarget.12510.

19.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

van der Meijde E, van den Eertwegh AJ, Linn SC, Meijer GA, Fijneman RJ, Coupé VM.

Cancer Inform. 2016 Jun 15;15:115-27. doi: 10.4137/CIN.S38122. eCollection 2016.

20.

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, Stoker J, Coupé VM.

Br J Radiol. 2016 Jul;89(1063):20150910. doi: 10.1259/bjr.20150910. Epub 2016 May 19.

21.

Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion.

Vellinga TT, den Uil S, Rinkes IH, Marvin D, Ponsioen B, Alvarez-Varela A, Fatrai S, Scheele C, Zwijnenburg DA, Snippert H, Vermeulen L, Medema JP, Stockmann HB, Koster J, Fijneman RJ, de Rooij J, Kranenburg O.

Oncogene. 2016 Oct 6;35(40):5263-5271. doi: 10.1038/onc.2016.60. Epub 2016 Mar 21.

PMID:
26996663
22.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2016 Aug 11;35(32):4179-87. doi: 10.1038/onc.2015.483. Epub 2016 Jan 11. Erratum in: Oncogene. 2017 Jun 15;36(24):3504.

23.

A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.

Goos JA, Coupé VM, van de Wiel MA, Diosdado B, Delis-Van Diemen PM, Hiemstra AC, de Cuba EM, Beliën JA, Menke-van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET Group.

Oncotarget. 2016 Jan 12;7(2):2123-34. doi: 10.18632/oncotarget.6188.

24.

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).

Goos JACM, Verbeek J, Geldof AA, Hiemstra AC, van de Wiel MA, Adamzek KA, Delis-Van Diemen PM, Stroud SG, Bradley DP, Meijer GA, Hoekstra OS, Fijneman RJA, Windhorst AD.

Nucl Med Biol. 2016 Jan;43(1):63-72. doi: 10.1016/j.nucmedbio.2015.08.007. Epub 2015 Sep 11.

PMID:
26432753
25.

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, Meijer GA.

Int J Cancer. 2016 Mar 1;138(5):1139-45. doi: 10.1002/ijc.29855. Epub 2015 Oct 23.

26.

High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.

van den Broek E, Dijkstra MJ, Krijgsman O, Sie D, Haan JC, Traets JJ, van de Wiel MA, Nagtegaal ID, Punt CJ, Carvalho B, Ylstra B, Abeln S, Meijer GA, Fijneman RJ.

PLoS One. 2015 Sep 16;10(9):e0138141. doi: 10.1371/journal.pone.0138141. eCollection 2015.

27.

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

Lenos K, Goos JA, Vuist IM, den Uil SH, Delis-van Diemen PM, Belt EJ, Stockmann HB, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJ, van Vliet SJ.

Oncotarget. 2015 Sep 22;6(28):26278-90. doi: 10.18632/oncotarget.4495.

28.

Proteomics of Colorectal Cancer in a Genomic Context: First Large-scale Mass Spectrometry-Based Analysis from the Cancer Genome Atlas.

Jimenez CR, Fijneman RJ.

Clin Chem. 2015 Sep;61(9):1126-8. doi: 10.1373/clinchem.2014.234807. Epub 2015 Feb 26. No abstract available.

29.

Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis.

Goos JA, de Cuba EM, Coupé VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Menke-Van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET Group.

Ann Surg. 2016 Jan;263(1):138-45. doi: 10.1097/SLA.0000000000001109.

PMID:
25563886
30.

The Potential of (TARGETED) MR Colonography as a Screening Tool for Colorectal Cancer: A Cost-Effectiveness Analysis.

Greuter MJ, Demirel E, Berkhof J, Fijneman RJ, Stoker J, Meijer GA, Coupé VM.

Value Health. 2014 Nov;17(7):A631-2. doi: 10.1016/j.jval.2014.08.2260. Epub 2014 Oct 26. No abstract available.

31.

Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework.

Van der Meijde E, van den Eertwegh AJ, Fijneman RJ, Meijer GA, Linn SC, Coupe VM.

Value Health. 2014 Nov;17(7):A562. doi: 10.1016/j.jval.2014.08.1862. Epub 2014 Oct 26. No abstract available.

32.

Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.

Goos JA, Hiemstra AC, Coupé VM, Diosdado B, Kooijman W, Delis-Van Diemen PM, Karga C, Beliën JA, Menke-van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET group; DeCoDe PET group.

Br J Cancer. 2014 Aug 12;111(4):749-55. doi: 10.1038/bjc.2014.354. Epub 2014 Jul 1.

33.

Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.

de Wit M, Kant H, Piersma SR, Pham TV, Mongera S, van Berkel MP, Boven E, Pontén F, Meijer GA, Jimenez CR, Fijneman RJ.

J Proteomics. 2014 Mar 17;99:26-39. doi: 10.1016/j.jprot.2014.01.001. Epub 2014 Jan 10.

PMID:
24418523
34.

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.

Labots M, Buffart TE, Haan JC, van Grieken NC, Tijssen M, van de Velde CJ, Grabsch HI, Ylstra B, Carvalho B, Fijneman RJ, Verheul HM, Meijer GA.

Cell Oncol (Dordr). 2014 Feb;37(1):41-52. doi: 10.1007/s13402-013-0162-4. Epub 2013 Dec 31.

PMID:
24379144
35.

Proteomics of differential extraction fractions enriched for chromatin-binding proteins from colon adenoma and carcinoma tissues.

Knol JC, de Wit M, Albrethsen J, Piersma SR, Pham TV, Mongera S, Carvalho B, Fijneman RJ, Meijer GA, Jiménez CR.

Biochim Biophys Acta. 2014 May;1844(5):1034-43. doi: 10.1016/j.bbapap.2013.12.006. Epub 2013 Dec 17.

PMID:
24361553
36.

Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis.

Goos JA, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beliën JA, Carvalho B, van den Tol MP, Verheul HM, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET group.

Br J Cancer. 2013 Oct 29;109(9):2445-52. doi: 10.1038/bjc.2013.608. Epub 2013 Oct 8.

37.

Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer.

Snoeren N, Emmink BL, Koerkamp MJ, van Hooff SR, Goos JA, van Houdt WJ, de Wit M, Prins AM, Piersma SR, Pham TV, Belt EJ, Bril H, Stockmann HB, Meijer GA, van Hillegersberg R, Holstege FC, Jimenez CR, Fijneman RJ, Kranenburg OW, Rinkes IH.

Br J Cancer. 2013 Sep 17;109(6):1636-47. doi: 10.1038/bjc.2013.489. Epub 2013 Sep 3.

38.

The role of KCNQ1 in mouse and human gastrointestinal cancers.

Than BL, Goos JA, Sarver AL, O'Sullivan MG, Rod A, Starr TK, Fijneman RJ, Meijer GA, Zhao L, Zhang Y, Largaespada DA, Scott PM, Cormier RT.

Oncogene. 2014 Jul 17;33(29):3861-8. doi: 10.1038/onc.2013.350. Epub 2013 Aug 26.

39.

Carcinoma origin dictates differential skewing of monocyte function.

Bögels M, Braster R, Nijland PG, Gül N, van de Luijtgaarden W, Fijneman RJ, Meijer GA, Jimenez CR, Beelen RH, van Egmond M.

Oncoimmunology. 2012 Sep 1;1(6):798-809.

40.

Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications.

de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR.

Clin Biochem. 2013 Apr;46(6):466-79. doi: 10.1016/j.clinbiochem.2012.10.039. Epub 2012 Nov 13. Review.

PMID:
23159294
41.

CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression.

Sillars-Hardebol AH, Carvalho B, Beliën JA, de Wit M, Delis-van Diemen PM, Tijssen M, van de Wiel MA, Pontén F, Meijer GA, Fijneman RJ.

Cell Oncol (Dordr). 2012 Aug;35(4):293-300. doi: 10.1007/s13402-012-0088-2. Epub 2012 Jun 19.

PMID:
22711543
42.

Lumican and versican are associated with good outcome in stage II and III colon cancer.

de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Bril H, Beliën JA, Fijneman RJ, Meijer GA.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S348-59. doi: 10.1245/s10434-012-2441-0. Epub 2012 Jun 19.

43.

Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer.

Fijneman RJ, de Wit M, Pourghiasian M, Piersma SR, Pham TV, Warmoes MO, Lavaei M, Piso C, Smit F, Delis-van Diemen PM, van Turenhout ST, Terhaar sive Droste JS, Mulder CJ, Blankenstein MA, Robanus-Maandag EC, Smits R, Fodde R, van Hinsbergh VW, Meijer GA, Jimenez CR.

Clin Cancer Res. 2012 May 1;18(9):2613-24. doi: 10.1158/1078-0432.CCR-11-1937. Epub 2012 Feb 20.

44.

Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism.

Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Terhaar Sive Droste J, Obulkasim A, van de Wiel M, van Criekinge W, Ylstra B, Fijneman RJ, Meijer GA.

Cell Oncol (Dordr). 2012 Feb;35(1):53-63. doi: 10.1007/s13402-011-0065-1. Epub 2012 Jan 26.

45.

TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.

Sillars-Hardebol AH, Carvalho B, Tijssen M, Beliën JA, de Wit M, Delis-van Diemen PM, Pontén F, van de Wiel MA, Fijneman RJ, Meijer GA.

Gut. 2012 Nov;61(11):1568-75. Epub 2011 Dec 29.

PMID:
22207630
46.

Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract.

Fijneman RJ, Anderson RA, Richards E, Liu J, Tijssen M, Meijer GA, Anderson J, Rod A, O'Sullivan MG, Scott PM, Cormier RT.

Cancer Sci. 2012 Mar;103(3):593-9. doi: 10.1111/j.1349-7006.2011.02189.x. Epub 2012 Jan 19.

47.

BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain.

Sillars-Hardebol AH, Carvalho B, Beliën JA, de Wit M, Delis-van Diemen PM, Tijssen M, van de Wiel MA, Pontén F, Fijneman RJ, Meijer GA.

J Pathol. 2012 Feb;226(3):442-50. doi: 10.1002/path.2983. Epub 2011 Oct 18.

PMID:
22009326
48.

The adenoma hunt in colorectal cancer screening: defining the target.

Sillars-Hardebol AH, Carvalho B, van Engeland M, Fijneman RJ, Meijer GA.

J Pathol. 2012 Jan;226(1):1-6. doi: 10.1002/path.3012. Epub 2011 Nov 14. Review.

PMID:
21984228
49.

Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression.

de Wit M, Jimenez CR, Carvalho B, Belien JA, Delis-van Diemen PM, Mongera S, Piersma SR, Vikas M, Navani S, Pontén F, Meijer GA, Fijneman RJ.

Gut. 2012 Jun;61(6):855-64. doi: 10.1136/gutjnl-2011-300511. Epub 2011 Sep 2.

PMID:
21890811
50.

Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.

Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delis-van Diemen PM, Tijssen M, van Essen HF, de Lange-de Klerk ES, Beliën JA, Stockmann HB, Meijer S, Meijer GA.

Eur J Cancer. 2011 Aug;47(12):1837-45. doi: 10.1016/j.ejca.2011.04.025. Epub 2011 May 27.

Supplemental Content

Loading ...
Support Center